Mood disorders are a prevalent mental health disorder. The adrenergic neurotransmission pathway presents an opportunity to determine whether genetic mutations impact antidepressant response. For this study, 163 patients with major depressive disorders were enrolled to measure treatment response using the Hamilton Depression Rating Scale (HAMD-17). More than half of the patients had never been treated with antidepressants previously. Patients were genotyped for 14 SNPs within ADRA1A, SLC6A2, ADRβ1, MAOA and COMT to determine the impact of adrenergic neurotransmission polymorphisms related in antidepressant response. Patients were treated mainly with SSRIs and TCAs. The difference in HAMD-17 scores between the measurement periods were defined...
BACKGROUND: Many antidepressants are substrates of P-glycoprotein, an efflux transporter in the bloo...
The severity of symptoms as well as efficacy of antidepressants in major depressive disorder (MDD) i...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
Mood disorders are a prevalent mental health disorder. The adrenergic neurotransmission pathway pres...
Background: There is sufficient evidence that interference of dopaminergic neurotransmission contrib...
Background Major depressive disorder (MDD) has a high personal and socio-economic burden and > 60...
Antidepressants are often only moderately successful in decreasing the severity of depressive sympto...
Background: Antidepressants are a first-line treatment for depression. However, only a third of indi...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
[[abstract]]BACKGROUND: Antidepressants are a first-line treatment for depression. However, only a t...
Growing evidence suggests the implication of brain plasticity in antidepressant drug (AD) efficacy. ...
Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably betwe...
Response to antidepressant (AD) treatment may be a more polygenic trait than previously hypothesized...
Response to antidepressant (AD) treatment may be a more polygenic trait than previously hypothesized...
BACKGROUND: Many antidepressants are substrates of P-glycoprotein, an efflux transporter in the bloo...
The severity of symptoms as well as efficacy of antidepressants in major depressive disorder (MDD) i...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
Mood disorders are a prevalent mental health disorder. The adrenergic neurotransmission pathway pres...
Background: There is sufficient evidence that interference of dopaminergic neurotransmission contrib...
Background Major depressive disorder (MDD) has a high personal and socio-economic burden and > 60...
Antidepressants are often only moderately successful in decreasing the severity of depressive sympto...
Background: Antidepressants are a first-line treatment for depression. However, only a third of indi...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
[[abstract]]BACKGROUND: Antidepressants are a first-line treatment for depression. However, only a t...
Growing evidence suggests the implication of brain plasticity in antidepressant drug (AD) efficacy. ...
Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably betwe...
Response to antidepressant (AD) treatment may be a more polygenic trait than previously hypothesized...
Response to antidepressant (AD) treatment may be a more polygenic trait than previously hypothesized...
BACKGROUND: Many antidepressants are substrates of P-glycoprotein, an efflux transporter in the bloo...
The severity of symptoms as well as efficacy of antidepressants in major depressive disorder (MDD) i...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...